Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT05199129

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05199129
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05199129. Randomized; double masking; primary purpose treatment. Start 2021-11-17 (actual); primary completion 2022-09-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
Condition
Hypertension
Intervention (Drug)
HCP1904-3
Intervention (Drug)
RLD2001-1
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct05199129
Content hash
144ef9fc04477f8b61367b21eb458efe198817284512930036f5e390edfd8c44